Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Summary

The purpose of this phase I trial is to evaluate the safety and feasibility of Canakinumab and Tislelizumab with Gemcitabine and Nab-paclitaxel in patients with pancreatic adenocarcinoma.

General Information

NCT#: NCT05984602
Study ID: 22-01205
Trial Phase: Phase I

Trial Sponsor: NYU Langone Health
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Tislelizumab, Canakinumab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search